Quantum Computing, Inc.

Executive Summary

SELL, Low conviction. QUBT rates a SELL, Low conviction for the next 6-12 months. The stock has already fallen 61.1% from its 52-week high, yet its 146.86x TTM P/S still assumes that acquisition-led revenue, customer acceptance, and Fab-2 capacity translate rapidly into durable economics. The company has substantial liquidity, so this is a valuation and delivery call rather than a near-term solvency call.

Investment Thesis

The market is valuing QUBT as if the move from experimental quantum computing to a scaled photonics and packaging supplier is already largely de-risked. It is not. The company has made a meaningful step forward: Q2 2026 revenue reached $5.6M and backlog reached $42.5M after the Enhanced acquisition. But backlog is not revenue, and management explicitly expects contracts to be performed over 12 to 18 months. That delay matters because the stock's valuation still embeds a highly favorable outcome before the company has demonstrated repeatable acceptance, yield, or gross-profit leverage.

The central dependency is conversion of the FY2026 revenue components, not another technical announcement. QCI excluding Enhanced is expected to generate $20M to $25M, while Enhanced is expected to contribute $7.07M to $16M. Those ranges offer a large growth path, but the company issued no formal consolidated guidance and said revenue timing depends on technical completion and customer acceptance. A business where 70% to 80% remains tied to government work, mainly subcontracting, is also less diversified than the headline backlog suggests.

The second dependency is cost control. Q2 operating expense reached $21.8M, including $7.3M of acquisition costs. Some of that expense is transitory, but the business must prove that revenue growth can absorb fixed manufacturing, engineering, and integration costs. A $75M prospective Fab-2 investment discussion is strategically understandable, yet a larger facility should follow demand validation rather than precede it.

The share price has already reset dramatically, sitting 61.1% below the 52-week high and 27.4% below the 200-day average. That improves asymmetry versus the peak, and the heavy short base could drive violent rallies on a clean revenue update. It does not make the current valuation cheap. Low conviction reflects the exceptional liquidity and real technology assets; the SELL reflects the gap between those assets and proven earnings power.

Key Metrics

Financial Strength

Liquidity is the major offset to an otherwise weak financial profile. The balance sheet has minimal leverage and unusually strong near-term coverage, while management cited $1.3B of cash, equivalents, and investments that can support acquisitions and capacity investment. However, cash generation is negative, margins remain deeply negative, and the Q2 cost base expanded sharply after the acquisition. Financial survival is not the concern; the return earned on the cash and on future fabrication spending is.

Competitive Position

QUBT's potential moat is vertical integration across photonic chip manufacturing, advanced packaging, quantum systems, and optimization software. Fab-2's approximately 60,000-wafer capacity and the Enhanced acquisition may create process knowledge and qualification barriers if utilization develops. That advantage is not yet durable: the company has no disclosed segment economics, limited commercial order history, and faces well-funded quantum peers plus non-quantum AI hardware alternatives.

Management & Guidance

Management did not issue formal consolidated guidance, reducing the precision of any FY2026 model. It reaffirmed QCI excluding Enhanced revenue of $20M-$25M and provided Enhanced contribution of $7.07M-$16M, while maintaining an Enhanced earn-out revenue target of $35M for FY2027. The ranges are directionally encouraging, but credibility is moderated by the stated 12-18 month backlog conversion cycle, customer-acceptance dependency, and the August 2026 EPS miss.

Segment Analysis

• Photonics products and foundry-related revenue (Not disclosed): Q2 2026 revenue of $5.6M was led by photonics products; management does not provide a segment revenue split.
• Enhanced acquisition revenue (Not disclosed): Management expects $7.07M-$16M of FY2026 contribution, but does not disclose historical segment revenue.
• Government contracting (Approximately 70%-80% of business): The mix is mainly subcontracting, which limits visibility into end-customer demand and can make timing uneven.
• Geography (Not disclosed): No geographic revenue disclosure was provided.

Capital Allocation

Capital allocation is expansionary, not shareholder-return oriented. LTM FCF through June 30, 2026 was -$0.1B, while the company reported $0.0B of buybacks and dividends; capital is being directed to integration, operating losses, and Fab-2 planning. Management discussed roughly $75M of prospective Fab-2 spending within a wider $50M-$100M planning range, but said it is not expected to spend anywhere near that amount this year, which is appropriately cautious but leaves the eventual return on capex untested.

Management Execution & Track Record

Management's 2024 Q4 call targeted foundry operations by March 2025, production and preorder deliveries in early Q2 2025, and proof-of-concept chips during Q2. The available evidence suggests that the commercial ramp took longer than that aspiration: Q2 2025 revenue was only $61K, while the material revenue step did not appear until Q2 2026 at $5.6M. The eventual operational progress is real, including Fab-2 launching ahead of schedule, Dirac-3 installation, and Neurawave's initial five-system order, but profitability has not followed, with Q2 2026 EBITDA margin at -146.6%. The earnings record is mixed but mostly better than low estimates, with six beats or meets in eight reported quarters, offset by a -840.0% miss in March 2025 and a -44.8% miss in August 2026. Management has moved from an organic foundry-launch story to an acquisition-led photonics and packaging strategy, and credibility is improving operationally but remains insufficient for high confidence.

Positioning & Flows

Institutional ownership is thin, with the top three institutions holding only 8.4%, while insiders own 11.5%. Short interest of 33.57%, equal to 7.2 days-to-cover, creates material squeeze potential around earnings but is principally a warning that the market disputes the commercial ramp. Options gamma is negative, with zero gamma at $6.98, slightly above spot, which can amplify downside volatility; call and put wall data were not usable in the supplied feed.

Bull Case

• Q2 2026 revenue reached $5.6M, versus $61K a year earlier and $3.7M in Q1, led by photonics products.
• Enhanced added advanced-packaging capacity and launched Fab-2 ahead of schedule; the facility currently supports approximately 60,000 wafers annually.
• The Planck Dynamics framework exceeds $10M and began with an order for five commercially ready Neurawave systems.
• Cash, equivalents, and investments were $1.3B in Q2 2026, offering unusually large funding capacity relative to the $1.5B market capitalization.

Bear Case

• The 146.86x TTM P/S multiple is 5.3x the 27.7x peer average despite no positive earnings base and no formal company-wide guidance.
• LTM operating margin was -775.5% and LTM FCF was -$0.1B through June 30, 2026, making self-funded expansion remote.
• Approximately 70%-80% of business is government contracting, mainly subcontracting, concentrating revenue timing and renewal risk.
• Short interest is 33.57% of float, or 67.35M shares, signaling substantial skepticism while also making the stock prone to sharp nonfundamental squeezes.

Valuation & Price Target

Engine price target $3.85 (-40.8% vs current), Low confidence.

• P/S Multiple: $0.07 (17% weight)
• Quality-adjusted: $6.76 (20% weight)
• DCF: $4.46 (8% weight)

The SELL matches the quant baseline rather than diverging from it. The engine's $3.85 target, or -40.8% from $6.50, is supported by a sales-quality blend: the standalone P/S method yields $0.07, the quality-adjusted method $6.76, and DCF $4.46. The balance sheet and $1.3B liquidity justify a low rather than high conviction because they can fund the ramp, but they do not cure -775.5% LTM operating margin, negative FCF, or the premium sales multiple. The three-firm Strong Buy sell-side consensus is low-signal context and does not outweigh those operating facts.

Risk Assessment

Risk score 52/100 (Moderate). The central downside risk is that the $42.5M backlog slips beyond management's 12-18 month conversion window, exposing a 146.86x TTM P/S valuation to a sharp reset.

The Bottom Line

QUBT rates a SELL, Low conviction. The company has more commercial substance than it did two years ago, but the stock still prices that progress as though backlog conversion and operating leverage are assured. The November 13 report must show that acquisition-led revenue is turning into accepted, recurring business rather than lumpy project revenue. A sustained run rate toward management's FY2026 component ranges, visible gross-profit leverage, and evidence that commercial customers reduce the government-linked mix would change the view.